Protara Therapeutics, Inc. Stock News

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionab

Protara Therapeutics (NASDAQ: TARA ) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Protara Therapeutics beat estimated earnings by 3.19%, reporting an EPS of … Full story available on Benzinga.com

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle in

- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with

ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.

Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor perfor